EA201291384A1 - Терапевтические агенты 976 - Google Patents

Терапевтические агенты 976

Info

Publication number
EA201291384A1
EA201291384A1 EA201291384A EA201291384A EA201291384A1 EA 201291384 A1 EA201291384 A1 EA 201291384A1 EA 201291384 A EA201291384 A EA 201291384A EA 201291384 A EA201291384 A EA 201291384A EA 201291384 A1 EA201291384 A1 EA 201291384A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic agents
azetidinyl
compound
melanin
prophylaxis
Prior art date
Application number
EA201291384A
Other languages
English (en)
Inventor
Сюзанне Дорис Маргит Бёкман-Винивартер
Марлене Фреденвалль
Андерс Карл Хогнер
Ларс Андерс Микаэль Йоханссон
Роберт Эндрю Джадкинс
Ланна Ли
Бьёрн Кристиан Ингвар Лёфберг
Пер Оскар Сверкер Фон Унге
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201291384A1 publication Critical patent/EA201291384A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Раскрыты азетидинильные соединения формулы Iкак определено в описании изобретения, фармацевтические композиции, содержащие азетидинильное соединение, и способ использования азетидинильного соединения в лечении или профилактике заболевания или состояния, связанного с меланин-концентрирующим гормоном.
EA201291384A 2010-07-06 2011-07-04 Терапевтические агенты 976 EA201291384A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06
PCT/GB2011/051256 WO2012004588A2 (en) 2010-07-06 2011-07-04 Therapeutic agents 976

Publications (1)

Publication Number Publication Date
EA201291384A1 true EA201291384A1 (ru) 2013-07-30

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291384A EA201291384A1 (ru) 2010-07-06 2011-07-04 Терапевтические агенты 976

Country Status (26)

Country Link
US (1) US8546375B2 (ru)
EP (1) EP2590969B1 (ru)
JP (1) JP5827683B2 (ru)
KR (1) KR20130041177A (ru)
CN (1) CN103209979B (ru)
AR (1) AR082113A1 (ru)
AU (1) AU2011275547B2 (ru)
BR (1) BR112013000296A2 (ru)
CA (1) CA2802832A1 (ru)
CL (1) CL2013000027A1 (ru)
CR (1) CR20130005A (ru)
CU (1) CU20130004A7 (ru)
DO (1) DOP2013000004A (ru)
EA (1) EA201291384A1 (ru)
EC (1) ECSP13012369A (ru)
ES (1) ES2527466T3 (ru)
GT (1) GT201300006A (ru)
HK (1) HK1182712A1 (ru)
MX (1) MX2012015102A (ru)
NI (1) NI201200196A (ru)
PE (1) PE20130781A1 (ru)
SA (1) SA111320581B1 (ru)
SG (1) SG186275A1 (ru)
TW (1) TW201206916A (ru)
UY (1) UY33487A (ru)
WO (1) WO2012004588A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
EP0783502A1 (en) 1995-08-02 1997-07-16 J. URIACH & CIA. S.A. New carboxamides with antifungal activity
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
WO2004011440A1 (ja) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1786790B1 (en) 2004-07-26 2009-06-03 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
DE602005011988D1 (de) 2004-10-18 2009-02-05 Lilly Co Eli Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen
SI1828177T1 (sl) 2004-12-17 2009-02-28 Lilly Co Eli Novi antagonisti mch receptorja
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
JP2008542365A (ja) 2005-05-31 2008-11-27 アストラゼネカ・アクチエボラーグ 新規なｍｃｈｒ１アンタゴニスト並びにｍｃｈｒ１媒介状態及び障害の処置のためのそれらの使用
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
DE602006018301D1 (de) * 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
US20090076064A1 (en) 2006-01-06 2009-03-19 Astrazeneca Ab Compounds
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
WO2008068265A1 (en) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
JP5269804B2 (ja) * 2006-12-14 2013-08-21 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体拮抗薬
WO2008131103A2 (en) 2007-04-17 2008-10-30 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
CN101790532B (zh) 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
JP2010536818A (ja) 2007-08-22 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３受容体アンタゴニストとしてのピロリジンアリール−エーテル
CA2702467C (en) * 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
JP5780954B2 (ja) * 2008-05-08 2015-09-16 エヴォテック・アクチエンゲゼルシャフト ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
EP2590969A2 (en) 2013-05-15
AR082113A1 (es) 2012-11-14
MX2012015102A (es) 2013-05-01
DOP2013000004A (es) 2013-04-30
WO2012004588A3 (en) 2012-08-09
NI201200196A (es) 2013-10-16
SG186275A1 (en) 2013-01-30
ES2527466T3 (es) 2015-01-26
SA111320581B1 (ar) 2014-06-17
AU2011275547B2 (en) 2015-10-29
US8546375B2 (en) 2013-10-01
HK1182712A1 (en) 2013-12-06
CN103209979B (zh) 2016-02-10
CA2802832A1 (en) 2012-01-12
EP2590969B1 (en) 2014-10-15
US20120010189A1 (en) 2012-01-12
CN103209979A (zh) 2013-07-17
JP2013535413A (ja) 2013-09-12
CU20130004A7 (es) 2013-05-31
BR112013000296A2 (pt) 2019-09-24
KR20130041177A (ko) 2013-04-24
JP5827683B2 (ja) 2015-12-02
PE20130781A1 (es) 2013-07-20
GT201300006A (es) 2014-11-06
AU2011275547A1 (en) 2013-02-07
UY33487A (es) 2012-02-29
CR20130005A (es) 2013-04-17
TW201206916A (en) 2012-02-16
WO2012004588A2 (en) 2012-01-12
ECSP13012369A (es) 2013-01-31
CL2013000027A1 (es) 2013-03-08

Similar Documents

Publication Publication Date Title
EA201290919A1 (ru) Индазольные соединения и их применение
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
BR112013018286A2 (pt) derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
WO2013040227A3 (en) Therapeutic compounds
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
IN2015DN01230A (en) Pyrrolopyrazoles as n type calcium channel blockers
UA117154C2 (uk) Антагоністи s1p3
EA201792264A1 (ru) Способы лечения воспалительных заболеваний